Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Vaishali Sanchorawala, Monique Minnema, Yvonne Efebera, Angela Dispenzieri, Ashutosh Wechalekar, Martha Grogan, Antoine Huart, Michael Rosenzweig, Brandon Blue, Faizi Jamal, Christopher Pericone, Sandra Vasey, Yuping Chen, Matteo Loi, NamPhuong Tran, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 691.

https://doi.org/10.1182/blood-2025-691

Published: 2025

Journal Articles

A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era

Blood (2025) 146 (Supplement 1): 577.

https://doi.org/10.1182/blood-2025-577

Published: 2025

Journal Articles

TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis

Murielle Roussel, Efstathios Kastritis, Stefan Schönland, K. Martin Kortüm, Bertrand Arnulf, Arnaud Jaccard, Sanjay Vara, Margaret Doyle, Jordan Schecter, Alexander Carpinteiro, Fiona Kwok, Giovanni Palladini, Monique Minnema, Mario Boccadoro, Pieter Sonneveld

Blood (2025) 146 (Supplement 1): 3974.

https://doi.org/10.1182/blood-2025-3974

Published: 2025

Journal Articles

WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia

Anne-Marie Becking, Pythia Nieuwkerk, Michelle Postek, Karima Amaador, Sophie Bernelot Moens, Linda Bronsgeest, Shirley D'Sa, Pierre Faubert, Carl Harrington, Paul Kitchen, David Macdonald, Monique Minnema, Alison McKinney, Lia Palomba, Ibrahim Tohidi-Esfahani, Judith Trotman, Andrew Warden, Marie José Kersten, Josephine Vos

Blood (2025) 146 (Supplement 1): 519.

https://doi.org/10.1182/blood-2025-519

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood (2024) 143 (8): 734–737.

https://doi.org/10.1182/blood.2023022937

Published: 2024

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios A Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon, Igor Blau

Blood (2016) 128 (22): 3331.

https://doi.org/10.1182/blood.V128.22.3331.3331

Published: 2016

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Saskia K. Klein, MD PhD, Esther G.M. De Waal, MD, Corien M. Eeltink, RN, MA, ANP, Paula F. Ypma, MD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD PhD, Bea Tanis, MD PhD, Monique S. Slee-Valentijn, MD, Monique Minnema, Heleen Visser-Wisselaar, PhD, Claudia Stege, MD, Niels W.C.J. van de Donk, MD PhD, Kazem Nasserinejad, MA, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3305.

https://doi.org/10.1182/blood.V128.22.3305.3305

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era

TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis

WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only